BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23052995)

  • 1. [Fabry disease : diagnosis and treatment].
    Üçeyler N; Sommer C
    Schmerz; 2012 Sep; 26(5):609-19. PubMed ID: 23052995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
    Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
    Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The neurological manifestations of Fabry disease. A review].
    Firsov KV; Kotov AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9):98-105. PubMed ID: 27735906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabry disease with special reference to neurological manifestations.
    Banerjee TK
    Eur Rev Med Pharmacol Sci; 2004; 8(6):275-81. PubMed ID: 15745387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stroke and Chronic Kidney Disease in Fabry Disease.
    Tapia D; Kimonis V
    J Stroke Cerebrovasc Dis; 2021 Sep; 30(9):105423. PubMed ID: 33160817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fabry disease.
    Germain DP
    Orphanet J Rare Dis; 2010 Nov; 5():30. PubMed ID: 21092187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
    Wang RY; Abe JT; Cohen AH; Wilcox WR
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
    Sasa H; Nagao M; Kino K
    Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological complications in Fabry disease.
    Dütsch M; Hilz MJ
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S243-50. PubMed ID: 21211673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fabry disease in children and the effects of enzyme replacement treatment.
    Pintos-Morell G; Beck M
    Eur J Pediatr; 2009 Nov; 168(11):1355-63. PubMed ID: 19242721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neurological manifestations of Fabry disease].
    Mendióroz M; Fernández-Cadenas I; Montaner J
    Rev Neurol; 2006 Dec 16-31; 43(12):739-45. PubMed ID: 17160925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A diagnosis of Fabry gastrointestinal disease by chance: a case report.
    Feriozzi S; Torre ES; Ranalli TV; Cardello P; Morrone A; Ancarani E
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):163-5. PubMed ID: 17273003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy.
    Hilz MJ; Brys M; Marthol H; Stemper B; Dütsch M
    Neurology; 2004 Apr; 62(7):1066-72. PubMed ID: 15079003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fabry disease: a treatable lysosomal storage disorder.
    Phadke SR; Mandal K; Girisha KM
    Natl Med J India; 2009; 22(1):20-2. PubMed ID: 19761154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anderson-Fabry disease in Austria.
    Lorenz M; Hauser AC; Püspök-Schwarz M; Kotanko P; Arias I; Zodl H; Kramar R; Paschke E; Voigtländer T; Sunder-Plassmann G
    Wien Klin Wochenschr; 2003 Apr; 115(7-8):235-40. PubMed ID: 12778775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy.
    Schiffmann R
    Acta Neurol Belg; 2006 Jun; 106(2):61-5. PubMed ID: 16898255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.
    Hoffmann B; Beck M; Sunder-Plassmann G; Borsini W; Ricci R; Mehta A;
    Clin J Pain; 2007; 23(6):535-42. PubMed ID: 17575495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
    Lenders M; Brand E
    J Am Soc Nephrol; 2018 Sep; 29(9):2265-2278. PubMed ID: 30093456
    [No Abstract]   [Full Text] [Related]  

  • 20. Enzyme replacement therapy of Fabry disease.
    Clarke JT; Iwanochko RM
    Mol Neurobiol; 2005 Aug; 32(1):43-50. PubMed ID: 16077182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.